Elevation of peripheral BDNF promoter methylation links to the risk of Alzheimer's disease.
PLoS One
; 9(11): e110773, 2014.
Article
em En
| MEDLINE
| ID: mdl-25364831
ABSTRACT
Brain derived neurotrophic factor (BDNF) has been known to play an important role in various mental disorders or diseases such as Alzheimer's disease (AD). The aim of our study was to assess whether BDNF promoter methylation in peripheral blood was able to predict the risk of AD. A total of 44 AD patients and 62 age- and gender-matched controls were recruited in the current case-control study. Using the bisulphite pyrosequencing technology, we evaluated four CpG sites in the promoter of the BDNF. Our results showed that BDNF methylation was significantly higher in AD cases than in the controls (CpG1 pâ=â10.021; CpG2 pâ=â0.002; CpG3 pâ=â0.007; CpG4 pâ=â0.005; average methylation pâ=â0.004). In addition, BDNF promoter methylation was shown to be significantly correlated with the levels of alkaline phosphatase (ALP), glucose, Lp(a), ApoE and ApoA in males (ALP râ=â-0.308, pâ=â0.042; glucose râ=â-0.383, pâ=â0.010; Lp(a) râ=â0.333, pâ=â0.027; ApoE râ=â-0.345, pâ=â0.032;), ApoA levels in females (râ=â0.362, pâ=â0.033), and C Reactive Protein (CRP) levels in both genders (males râ=â-0.373, pâ=â0.016; females râ=â-0.399, pâ=â0.021). Our work suggested that peripheral BDNF promoter methylation might be a diagnostic marker of AD risk, although its underlying function remains to be elaborated in the future.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Regiões Promotoras Genéticas
/
Fator Neurotrófico Derivado do Encéfalo
/
Metilação de DNA
/
Doença de Alzheimer
Tipo de estudo:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article